Karyopharm Therapeutics Inc. (KPTI) Income Statement
KPTI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKPTI revenue and net income
Where KPTI's revenue goes
2025Each bar shows an amount and its share of revenue. KPTI kept −134.2% of revenue as net income.
KPTI profit margins
KPTI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +0.6% | −2.4% | +6.2% | +89.1% |
| Gross profit | +0.6% | −2.6% | +5.9% | +88.3% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KPTI quarterly EPS vs estimates
Karyopharm Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 2, 2026 (estimate $-1.15).
KPTI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M | $108.1M | $40.9M | $30.3M | $1.6M | $154,000 |
| Cost of revenue | $5.9M | $6.0M | $4.9M | $5.2M | $3.4M | $2.7M | $2.4M | $161.4M | $107.3M | $86.9M |
| Gross profit | $140.1M | $139.2M | $141.1M | $151.9M | $206.4M | $105.4M | $38.5M | −$131.0M | $1.6M | $154,000 |
| Research & development | $125.6M | $143.2M | $138.8M | $148.7M | $160.8M | $150.8M | $122.3M | $161.4M | $107.3M | $86.9M |
| Sales, general & admin | $105.2M | $115.4M | $131.9M | $145.4M | $143.8M | $126.4M | $105.4M | $48.8M | $24.9M | $23.9M |
| Total operating expenses | $230.8M | $258.7M | $270.6M | $294.1M | $304.7M | $277.2M | $227.8M | $210.2M | $132.1M | $110.9M |
| Operating income | −$90.7M | −$119.4M | −$129.5M | −$142.2M | −$98.3M | −$171.8M | −$189.3M | −$179.9M | −$130.5M | −$110.7M |
| Interest income | $2.8M | $7.4M | $9.8M | $2.4M | $582,000 | $2.8M | $5.4M | $4.0M | $1.7M | $1.3M |
| Interest expense | $45.8M | $37.4M | $23.8M | $25.0M | $26.0M | $27.1M | $15.6M | $2.5M | $1.6M | $1.3M |
| Income before taxes | −$196.0M | −$76.4M | −$142.8M | −$164.9M | −$123.8M | −$196.0M | −$199.6M | −$178.4M | −$128.9M | −$109.4M |
| Income taxes | $43,000 | $57,000 | $323,000 | $369,000 | $268,000 | $309,000 | $40,000 | $26,000 | $63,000 | $139,000 |
| Net income | −$196.0M | −$76.4M | −$143.1M | −$165.3M | −$124.1M | −$196.3M | −$199.6M | −$178.4M | −$129.0M | −$109.6M |
| EBITDA | −$149.9M | −$38.6M | −$118.4M | −$139.3M | −$97.0M | −$167.9M | −$182.9M | −$175.2M | −$129.8M | −$110.0M |
| EPS (diluted) | −$12.89 | −$16.64 | −$13.71 | −$30.45 | −$25.65 | −$40.95 | −$48.45 | −$33.51 | −$30.80 | −$34.85 |
| Gross margin | 95.9% | 95.9% | 96.6% | 96.7% | 98.4% | 97.5% | 94.1% | −431.9% | 100.0% | 100.0% |
| Operating margin | −62.1% | −82.2% | −88.7% | −90.5% | −46.8% | −159.0% | −462.9% | −593.0% | −8,133.2% | −71,903.9% |
| Net margin | −134.2% | −52.6% | −98.0% | −105.2% | −59.1% | −181.6% | −488.1% | −588.1% | −8,036.4% | −71,153.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.4M | $35.1M | $34.1M | $44.0M | $37.9M | $30.0M | $30.5M | $38.8M | $42.8M | $33.1M | $33.7M | $36.0M |
| Cost of revenue | $1.1M | $1.4M | $1.5M | $2.1M | $1.1M | $1.3M | $1.3M | $1.3M | $1.6M | $2.0M | $1.6M | $911,000 |
| Gross profit | $32.3M | $33.7M | $32.6M | $41.9M | $36.9M | $28.7M | $29.2M | $37.5M | $41.2M | $31.1M | $32.2M | $35.1M |
| Research & development | $29.9M | $33.8M | $27.7M | $30.5M | $32.8M | $34.6M | $33.3M | $36.1M | $38.3M | $35.3M | $39.3M | $35.6M |
| Sales, general & admin | $25.9M | $26.7M | $22.8M | $26.6M | $28.5M | $27.4M | $27.2M | $27.6M | $31.1M | $29.5M | $30.7M | $30.8M |
| Total operating expenses | $54.9M | $60.5M | $50.4M | $57.2M | $61.3M | $62.0M | $60.5M | $63.8M | $69.3M | $64.9M | $70.0M | $66.4M |
| Operating income | −$22.5M | −$26.8M | −$17.8M | −$15.2M | −$24.4M | −$33.3M | −$31.3M | −$26.3M | −$28.1M | −$33.8M | −$37.8M | −$31.3M |
| Interest income | $722,000 | $511,000 | $607,000 | $553,000 | $613,000 | $1.0M | $1.5M | $1.8M | $1.9M | $2.2M | $2.5M | $2.8M |
| Interest expense | $13.1M | $12.6M | $12.6M | $11.0M | $11.2M | $11.0M | $11.2M | $11.4M | $8.9M | $5.9M | $6.2M | $6.1M |
| Income before taxes | −$67.0M | −$22.4M | −$102.3M | −$33.1M | −$37.2M | −$23.4M | −$30.9M | −$32.0M | $23.9M | −$37.3M | −$41.7M | −$34.5M |
| Income taxes | — | $1,000 | −$67,000 | $34,000 | $40,000 | $36,000 | −$109,000 | $28,000 | $67,000 | $71,000 | $130,000 | $12,000 |
| Net income | −$67.0M | −$22.4M | −$102.2M | −$33.1M | −$37.3M | −$23.5M | −$30.8M | −$32.1M | $23.8M | −$37.4M | −$41.8M | −$34.5M |
| EBITDA | −$53.9M | −$9.8M | −$89.6M | −$22.5M | −$25.9M | −$12.4M | −$19.6M | −$20.6M | $32.9M | −$31.3M | −$35.4M | −$28.3M |
| EPS (diluted) | −$2.32 | −$1.24 | −$2.23 | −$3.82 | −$4.07 | −$2.77 | −$3.60 | −$3.90 | −$4.34 | −$4.80 | −$0.36 | −$4.50 |
| Gross margin | 96.8% | 96.1% | 95.6% | 95.2% | 97.2% | 95.7% | 95.6% | 96.6% | 96.4% | 94.0% | 95.4% | 97.5% |
| Operating margin | −67.4% | −76.3% | −52.4% | −34.6% | −64.3% | −110.8% | −102.4% | −67.8% | −65.7% | −101.9% | −112.0% | −86.8% |
| Net margin | −200.5% | −63.9% | −299.9% | −75.2% | −98.2% | −78.2% | −100.8% | −82.7% | 55.6% | −112.8% | −124.0% | −95.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KPTI's financial statements (latest annual report filed February 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KPTI financial results
In fiscal year 2025 (ended December 31, 2025), Karyopharm Therapeutics reported revenue of $146.1 million, up 0.6% from the year before. It had a net loss of $196.0 million, a net profit margin of −134.2%. Diluted earnings per share came to −$12.89. Over five years revenue grew at an average rate of 6.2% a year.
See the KPTI stock overview for the latest quote and news, or the KPTI chart for price history and technical indicators.
KPTI income statement FAQ
What is Karyopharm Therapeutics's annual revenue?
Karyopharm Therapeutics reported total revenue of $146.1 million for fiscal year 2025, which ended on December 31, 2025. That was up 0.6% from $145.2 million the previous year.
Is Karyopharm Therapeutics profitable?
No. Karyopharm Therapeutics reported a net loss of $196.0 million in fiscal 2025, a net profit margin of −134.2%; its operating margin was −62.1%.
What is Karyopharm Therapeutics's gross margin?
Karyopharm Therapeutics's gross margin was 95.9% in fiscal 2025: for every $100 of revenue, Karyopharm Therapeutics kept $96 after the direct cost of its products and services.
How much does Karyopharm Therapeutics spend on research and development?
Karyopharm Therapeutics spent $125.6 million on research and development in fiscal 2025, 86.0% of revenue.
How fast is Karyopharm Therapeutics growing?
Revenue grew 6.2% a year on average over the last five fiscal years, from $108.1 million to $146.1 million.
What are Karyopharm Therapeutics's earnings per share?
Karyopharm Therapeutics earned $-12.89 per diluted share in fiscal 2025, compared with $-16.64 a year earlier.
When will Karyopharm Therapeutics report its next earnings?
Karyopharm Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 2, 2026.
When does Karyopharm Therapeutics's fiscal year end?
Karyopharm Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 13, 2026.